Stockscreener 앱 받기
91.70
1.10%
-1.02
시간 외 거래:
91.80
0.10
+0.11%
전일 마감가:
$92.72
열려 있는:
$92.62
하루 거래량:
11.97M
Relative Volume:
0.97
시가총액:
$159.34B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
25.55
EPS:
3.5895
순현금흐름:
$7.40B
1주 성능:
-9.71%
1개월 성능:
-13.05%
6개월 성능:
-28.33%
1년 성능:
-30.39%
1일 변동 폭
$91.59
$94.04
1주일 범위
$91.59
$99.00
52주 변동 폭
$91.59
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
91.70 | 161.12B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
329.35 | 125.35B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
83.22 | 105.28B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.87 | 88.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.53 | 45.96B | 6.07B | 1.06B | 1.34B | 1.8063 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Coagulation Analyzer Market Size to Reach a Valuation of USD 7.87 Billion by 2035; Increasing Incidence of Blood Disorders to Propel Market Expansion Globally | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Tops List of Oversold Healthcare Stocks - GuruFocus
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Abbott is the most oversold healthcare stock as Q1 earnings roll on - MSN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
Commentary: There is a hidden cost to the Abbott verdict for premature babies - The Daily Gazette
Abbott has positive drug-eluting scaffold data - Drug Delivery Business
Abbott Laboratories (ABT) Stock Down 3.4% -- Now Undervalued? GF Score: 87/100 - GuruFocus
Abbott Laboratories Stock (ABT) Moved Down by 3.33% on Apr 21: Key Drivers Unveiled - TradingKey
Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity - Seeking Alpha
Abbott Laboratories stock hits 52-week low at 93.91 USD - Investing.com
Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St.
Is the Options Market Predicting a Spike in Abbott Laboratories Stock? - Zacks Investment Research
UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT) - The Globe and Mail
Abbott Laboratories: Buy The Dip On This Dividend King (NYSE:ABT) - Seeking Alpha
Leerink Partners Adjusts PT on Abbott Laboratories to $106 From $119, Maintains Market Perform Rating - marketscreener.com
Argus Adjusts Price Target on Abbott Laboratories to $125 From $140, Maintains Buy Rating - marketscreener.com
Leerink cuts Abbott Labs stock price target on mixed results - Investing.com
Leerink cuts Abbott Labs stock price target on mixed results By Investing.com - Investing.com Canada
Abbott Laboratories Stock Hands $28 Bil Back – Worth a Look? - Trefis
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Abbott Laboratories Stock Hands $28 Bil BackWorth a Look? - Trefis
Lobbying Update: $1,410,000 of ABBOTT LABORATORIES lobbying was just disclosed - Quiver Quantitative
Boston Scientific (BSX) Q1 Earnings: What To Expect - TradingView
How Investors May Respond To Abbott (ABT) Cancerguard Data Amid Legal And Earnings Pressures - simplywall.st
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom - The Motley Fool
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account - Investing.com Australia
Abbott Laboratories: The Constraint Is Integration As $3 Billion Bet Adds Complexity! - Smartkarma
UBS Adjusts Abbott Laboratories Price Target to $135 From $158, Maintains Buy Rating - Moomoo
Abbott Wins Glucose Monitor Sales Ban On Appeal At UPC - Law360
Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story - Yahoo Finance
Has the Abbott Laboratories sell-off finally created an entry point? - MSN
SCS Injury Lawsuit Alleges Unlicensed Abbott Representatives Modified Device After Implantation - AboutLawsuits.com
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Guidance Cut - Quiver Quantitative
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Bernstein SocGen cuts Abbott Labs stock price target on weak quarter - Investing.com Canada
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - 24/7 Wall St.
Abbott price target lowered to $143 from $144 at Barclays - TipRanks
Intuitive Surgical (ISRG) Q1 Earnings: What To Expect - TradingView
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to drive sustained growth f - AD HOC NEWS
Abbott Laboratories in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q1; nutrition falls - MSN
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
ABT: Abbott Laboratories Lowers Earnings Outlook Despite Revenue Beat - GuruFocus
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $115 to $144 - Moomoo
How Abbott is Changing the Way We Treat AFib - Tomorrow's World Today
Abbott Laboratories (ABT) Margin Drop To 13.9% Challenges Bullish Earnings Narratives - simplywall.st
Ninety One UK Ltd Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Ninety One North America Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Abbott Laboratories stock (US0028241000): Why diagnostics strength is suddenly worth a closer look - AD HOC NEWS
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
1.22%
자본화:
|
볼륨(24시간):